Venous disease affects one in four people and ranks as the 4th most common chronic disease in the world. This progressive venous disease culminates in debilitating venous leg ulcers that destroy quality of life for sufferers. It places a huge burden on health care systems, representing up to 3% of total healthcare budgets of western countries.
Only 1.3% of the 120 million people in the US & Europe who suffer from venous disease currently receive treatment each year.
BioVena™ offers an unrivalled lower risk treatment which will allow more patients who suffer from venous disease to access effective treatment*.
* – BioVena™ is currently for Investigational Research Use Only. US & EU regulatory approval is anticipated in 2022.